Why “enforcement discretion” is not the same as “legal”

Most online sources describing personal importation of medication say something like “it is legal under FDA policy.” That phrasing is misleading. The conduct is technically prohibited by federal statute. What the FDA has done is announce that it will generally choose not to enforce against patients who meet certain conditions — a posture known as enforcement discretion. This page explains why the difference matters.

What does the statute actually say?

The relevant federal statute is the Federal Food, Drug, and Cosmetic Act. Section 505, codified at 21 U.S.C. § 355, prohibits introducing a “new drug” into interstate commerce without an approved application. Section 801, codified at 21 U.S.C. § 381, authorizes refusal of admission to any drug offered for import that appears to violate the Act — including drugs unapproved in the United States.[1][2] These provisions are the default rule: personal importation of unapproved drugs is presumptively prohibited.

The FDA’s own published guidance is unambiguous. The agency’s “Personal Importation” page states that in most circumstances it is illegal for individuals to import drugs into the U.S. for personal use, and that a drug approved abroad but unapproved in the U.S. is illegal to import.[3] Customs and Border Protection’s traveler guidance states the same baseline.[4] The statutory framework contains no exemption for personal importation. What patients call the “policy” is not a statutory authorization — it is an internal FDA enforcement posture, stated in agency guidance, that the agency could revise or revoke. The Congressional Research Service describes the framework the same way: current law generally does not permit individuals to import prescription drugs for their own use, but directs the Secretary to exercise discretion to permit personal imports that are obviously for personal use and do not appear to present an unreasonable risk.[5]

What does “enforcement discretion” mean in administrative law?

Enforcement discretion is the principle that a federal agency with authority to enforce a law may choose how and whether to exercise that authority in a given case. The principle is grounded in the Supreme Court’s decision in Heckler v. Chaney (1985), which held that an agency’s decision not to take an enforcement action is presumptively unreviewable by the courts under Section 701(a)(2) of the Administrative Procedure Act.[6][7] The case arose in a different setting — petitioners asked the FDA to act against the use of FDA-regulated drugs in lethal injections, and the FDA declined — but the principle applies broadly to FDA enforcement decisions. The Court held that the enforcement provisions of the FFDCA commit complete discretion to the Secretary to decide how and when they are exercised.[6]

One nuance matters, and the Court was explicit about it: the non-enforcement decision is only presumptively unreviewable, and the presumption can be rebutted where the substantive statute provides meaningful standards limiting the agency’s discretion.[7] But for personal importation, two consequences follow:

• The discretion is the agency’s, not the patient’s. The FDA may exercise it broadly, narrowly, or revoke it. A patient relying on current discretion is relying on a posture that exists at the agency’s pleasure.
• Courts generally treat agency non-enforcement decisions as presumptively unreviewable. If the FDA changed its enforcement posture, a patient would face substantial legal barriers to compelling continued non-enforcement.

What does the FDA’s personal importation guidance actually say?

The FDA states its enforcement-discretion framework in the Regulatory Procedures Manual, Chapter 9, Subchapter 9-2. This is internal guidance for FDA field personnel — it tells staff when to consider releasing a personal-import shipment rather than refusing admission. It is not a statute, not a regulation, and creates no rights enforceable by patients.[8] Summarized on the FDA’s public page, the framework identifies when FDA personnel may consider a more permissive decision on a personal-import shipment of a prescription drug for a serious condition: the product is for a serious condition for which effective treatment may not be available domestically; there is no known commercialization or promotion to U.S. residents; the product does not represent an unreasonable risk; the consumer affirms in writing that it is for personal use; and the quantity is generally not more than a three-month supply, with either the U.S.-licensed treating doctor named or evidence the product continues a treatment begun abroad.[3]

Two points patients most often misread:

The “no effective U.S. treatment available” criterion is what most often fails for cost-driven imports

A patient who imports a foreign generic of a U.S.-branded drug because the U.S. price is unaffordable is importing for a serious condition — but effective U.S. treatment is available, because the drug is FDA-approved and sold here. The barrier is cost, not availability. The FDA has stated its personal-importation policy was not normally intended as a way for consumers to obtain lower-priced drugs, but rather to allow access to treatments not otherwise available in the United States.[5] The framework was not designed to address cost barriers to FDA-approved drugs.

The three-month benchmark is a threshold, not a guarantee

The manual uses the roughly three-month supply figure to evaluate whether a shipment is for personal use or suggests commercial distribution.[8] Quantities beyond that benchmark are more likely to be treated as commercial, which removes the shipment from the enforcement-discretion framework entirely.

What the framework does not cover

Several categories fall outside the framework entirely. Commercial shipments — including orders from a foreign pharmacy operating as a commercial supplier to U.S. customers, regardless of an individual buyer’s intent — are generally not amenable to enforcement discretion.[8] Controlled substances are governed by a separate DEA framework; the FDA’s discretion does not apply, and the DEA generally decides whether a controlled substance may be imported for personal use (see the companion page on controlled substances).[3] Drugs subject to FDA Import Alerts, such as Import Alert 66-57 covering foreign-manufactured unapproved prescription drugs distributed to U.S. individuals including via online pharmacies, are subject to automatic detention.[9] And state pharmacy law is a separate layer: federal enforcement discretion does not preempt a state board that prohibits possession of foreign-sourced medication (see the companion page on state pharmacy boards).

The framework is not permanent

The FDA’s enforcement-discretion posture has shifted over time and remains subject to revision. The agency periodically issues new guidance, revises Import Alerts, and updates the manual. In 2019, HHS and the FDA announced a “Safe Importation Action Plan” proposing two pathways to facilitate importation of certain drugs; in October 2020, HHS implemented the first pathway by final rule under Section 804 of the FFDCA, allowing states and tribes to propose time-limited programs to import certain drugs from Canada.[5][10] That program addresses state-sponsored wholesale importation, not individual personal use — but the broader point holds: federal importation policy is actively contested.

The FDA itself states that Import Alerts represent the agency’s current guidance to field personnel, do not create or confer rights on any person, and do not bind the FDA or the public. The same is true of the Regulatory Procedures Manual.[8][9] A patient building a long-term medication strategy on the assumption that current discretion will continue indefinitely is making a forecast about agency policy. Policy may continue as it is; it may also change.

This site does not provide legal advice. The framework summarized here is general information about a federal enforcement posture. Patients with specific legal questions should consult a U.S.-licensed attorney with experience in FDA regulatory or healthcare law.